Edition:
United States

Intellia Therapeutics Inc (NTLA.OQ)

NTLA.OQ on NASDAQ Stock Exchange Global Market

21.71USD
20 Apr 2018
Change (% chg)

$-0.23 (-1.05%)
Prev Close
$21.94
Open
$21.80
Day's High
$22.19
Day's Low
$21.29
Volume
182,934
Avg. Vol
347,185
52-wk High
$35.99
52-wk Low
$11.15

Chart for

About

Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that... (more)

Overall

Beta: --
Market Cap(Mil.): $920.23
Shares Outstanding(Mil.): 42.39
Dividend: --
Yield (%): --

Financials

  NTLA.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -1.86 -- --
ROI: -22.03 -0.74 13.19
ROE: -26.46 -2.80 15.00

BRIEF-Intellia Therapeutics Reports Qtrly Net Loss Per Share $0.61

* INTELLIA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 14 2018

BRIEF-Intellia Therapeutics Names John Leonard, M.D., President And CEO

* INTELLIA THERAPEUTICS NAMES JOHN LEONARD, M.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER

Dec 18 2017

BRIEF-Intellia Therapeutics prices public offering of 6.3 mln shares at $24 per share

* Intellia Therapeutics announces pricing of public offering of common stock

Nov 01 2017

BRIEF-Intellia Therapeutics announces proposed public offering of common stock

* Intellia therapeutics announces proposed public offering of common stock

Nov 01 2017

BRIEF-Intellia Therapeutics Q3 loss per share $‍0.44​

* Intellia therapeutics announces third quarter 2017 financial results

Oct 31 2017

BRIEF-Intellia Therapeutics Q3 revenue $65 mln

* Intellia Therapeutics announces third quarter 2017 financial results

Oct 31 2017

Earnings vs. Estimates